vaccine

  1. syamfx2020

    Pfizer the next game changer

    As per the recent report, Pfizer (NYSE: PFE) will likely be the first vaccine to reach the market. This one is the most heavily anticipated candidate by far is BNT162b2, the COVID-19 vaccine developed in partnership with German biotech BioNTech. On Wednesday, the regulators in the United...
  2. Zulbahri_GB

    Intraday Forex Wednesday, December 2 (USDJPY, EURUSD, & etc.) Bets on more easing from the U.S. Fed weighed on the dollar as riskier currencies rose.

    Hi everyone. This observation is made around 5:00 UTC today, with 30 minutes time frames. The Resistance and Support Line were constructed according to Fibonacci retrenchment. Any discussion is welcomed. Asian shares shed early gains from a strong overnight Wall Street lead, as some investors...
  3. syamfx2020

    Coronavirus vaccine: AstraZeneca join the lead

    British Pharmaceutical giant AstraZeneca (NASDAQ: AZN) reported the late-stage trials showed its COVID-19 vaccine was highly effective. AstraZeneca became the third pharmaceutical firm to report its effective coronavirus vaccine, only a few days after US biotech firms Moderna and Pfizer said...
  4. Zulbahri_GB

    Intraday Forex Tuesday, November 24 (USDJPY, EURUSD, & etc.) Risk-sensitive currencies gained on optimism of vaccine news and new U.S. administration

    Hi everyone. This observation is made around 5:00 UTC today, with 15 minutes time frames. The Resistance and Support Line were constructed according to Fibonacci retrenchment. Any discussion is welcomed. Asian stocks poised to trade mostly higher on Tuesday as investors bet on a return to...
  5. syamfx2020

    Why J&J stock slips despite strong Q3 earnings

    Johnson & Johnson (NYSE: JNJ) reported better-than-expected third-quarter financial results on Tuesday. The drugmaker raised its full-year guidance, saying it now expects per-share earnings of between $7.95 and $8.05, up from its previous forecast in July of between $7.75 and $7.95. "Our...
  6. syamfx2020

    AstraZeneca Covid-19 vaccine trial would resume shortly

    As per the recent update, the British biotech firm AstraZeneca (LON: AZN) would resume its trials for the experimental COVID-19 vaccine next week. On Tuesday, Pharmaceutical giant AstraZeneca suspended the late-stage trials after an illness in a study subject in Britain. The patient was...
  7. syamfx2020

    Why shares of Moderna jumped 6% on Wednesday

    American Biotechnology firm, Moderna (NASDAQ: MRNA) shares closed in positive for the second consecutive day. The $MRNA stock closed more than 6% higher on Wednesday after the early data of its experimental COVID-19 vaccine showed comparable immune response between older and younger volunteers...
Top